Seqirus, part of the CSL Group, is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, the two businesses joined forces to create Seqirus, now the second largest influenza vaccine company in the world. With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus has a workforce of over 2,000 employees, significant manufacturing capacity and a commercial presence in over 20 countries. In Australia and New Zealand, Seqirus markets a comprehensive range of vaccines and speciality pharmaceutical products. It also manufactures products of national significance for Australia, including antivenoms and Q fever vaccine.

Website: http://www.seqirus.com

Employees: 1082

HQ: N/A

Location: Maidenhead, SL6, United Kingdom

Revenue: 100 - 500 Million

Seqirus (NZ) Ltd is a leading biotech company that specializes in developing and manufacturing innovative vaccines and pharmaceuticals. If you're looking for contact information for Seqirus (NZ) Ltd, you've come to the right place. At ConnectPlex.ai, we provide accurate and up-to-date contact information for millions of companies across the globe, including Seqirus (NZ) Ltd. Our extensive database contains contact details for key decision-makers, executives, and other professionals in the company, making it easy for you to connect with the right person and grow your business. Whether you're looking to collaborate with Seqirus (NZ) Ltd or want to inquire about their products and services, our platform is the perfect place to start. Our user-friendly interface and advanced search filters allow you to quickly find the contact information you need, saving you time and effort. With ConnectPlex.ai, you can connect with people working in Seqirus (NZ) Ltd and expand your professional network in no time. Start your search today and discover the power of ConnectPlex.ai!

Seqirus (NZ) Ltd is a leading global company in the pharmaceutical industry, specializing in the research, development, and manufacturing of influenza vaccines. With a rich history dating back to 2015, Seqirus was formed by the merger of bioCSL and the influenza vaccines business previously owned by Novartis. The company has since grown to become the second-largest influenza vaccine company in the world, with a strong presence in over 20 countries. Seqirus has a diverse portfolio of products, including vaccines and specialty pharmaceuticals, which are marketed and distributed across Australia and New Zealand. The company's state-of-the-art manufacturing facilities are located in the US, UK, Germany, and Australia, allowing for efficient and effective production of high-quality products. Seqirus is committed to pandemic preparedness and plays a vital role in the prevention and control of influenza globally. The company boasts a skilled workforce of over 3,000 employees, each dedicated to the mission of protecting public health. Seqirus's leadership team includes experienced professionals with expertise in various fields, such as Andy Norman, Director CMO Quality; Federico Iaschi, Senior Manager Information Security C|CISO-CISSP-CISM-CRISC-CGEIT-MBCS-ISO27001 LA-Prince2-MoR-ITIL; Ian Herd, IT Project Manager & Service Owner - Product Security | Serialisation | Track and Trace; Jonathan Muir, Sr Manager CE/CMO; and Maura Cambiaggi, Director Commercial Operations Italy - Managing Director Seqirus Srl. Seqirus (NZ) Ltd is a prime example of a company that is dedicated to improving public health and well-being. Their commitment to research, development, and manufacturing of high-quality vaccines and pharmaceuticals has made them a leader in the industry. With a strong presence in over 20 countries and a talented team of professionals, Seqirus is poised to continue making a positive impact on global health for years to come.

Seqirus is a new global company that makes influenza vaccines. It was created by combining two other companies, bioCSL and Novartis' influenza vaccine business. Seqirus is now one of the largest influenza vaccine companies in the world. It has research and production expertise and manufacturing plants in several countries, including the US, UK, Germany, and Australia. Seqirus works with governments and health organizations to prepare for and prevent pandemics. It also sells its vaccines and specialty pharmaceutical products in over 20 countries. In Australia and New Zealand, Seqirus sells a wide range of vaccines and other products, including antivenoms and Q fever vaccine, which are important for the health and well-being of people in those countries.